Core Viewpoint - The company reported a revenue of RMB 56.4 million for the six months ending June 30, 2025, primarily from the sales of Isuparaglutide α in China, with a gross profit of RMB 50.5 million and a gross margin of 89.4% [1] Group 1: Financial Performance - Revenue for the period reached RMB 56.4 million, mainly driven by Isuparaglutide α sales in China [1] - Gross profit amounted to RMB 50.5 million, reflecting a high gross margin of 89.4% [1] - Research and development expenses increased from RMB 51.9 million in the previous year to RMB 99.1 million, attributed to rising raw material costs and increased clinical trial expenses [1] Group 2: Research and Development - The increase in R&D expenses was due to a RMB 18.1 million rise in raw material costs and a RMB 29.5 million increase in expenses related to preclinical research and clinical trials [1] - The company is actively pursuing global expansion of Isuparaglutide α for Type 2 Diabetes (T2D) treatment and advancing clinical development for obesity and overweight indications [1] Group 3: Regulatory Approvals - In June 2025, the company received BLA approval for Isuparaglutide α for T2D treatment in Macau and submitted BLA applications in Southeast Asia [2] - Plans are in place to submit another BLA application in Latin America in the second half of 2025, with intentions to seek further approvals in other jurisdictions to address unmet medical needs [2]
银诺医药-B(02591.HK)中期业绩：上半年收入5640万元，核心产品商业化及全球拓展加速